biostudies-literatureUnknown6(7)Millucci L<h4>Aims</h4>Atrial Natriuretic Peptide (ANP)-containing amyloid is frequently found in the elderly heart. No data exist regarding ANP aggregation process and its link to pathologies. Our aims were: i) to experimentally prove the presumptive association of Congestive Heart Failure (CHF) and Isolated Atrial Amyloidosis (IAA); ii) to characterize ANP aggregation, thereby elucidating IAA implication in the CHF pathogenesis.<h4>Methods and results</h4>A significant prevalence (85%) of IAA was immunohistochemically proven ex vivo in biopsies from CHF patients. We investigated in vitro (using Congo Red, Thioflavin T, SDS-PAGE, transmission electron microscopy, infrared spectroscopy) ANP fibrillogenesis, starting from α-ANP as well as the ability of dimeric β-ANP to promote amyloid formation. DifPloS onee21870https://www.ebi.ac.uk/biostudies/studies/S-EPMC3144199biostudies-literatureDifferent factors affecting human ANP amyloid aggregation and their implications in congestive heart failure.PMC3144199Tanganelli PSantucci AGhezzi LLaschi MConsumi MSpreafico ABraconi DMagnani ABernardini GMillucci LLupetti PPaccagnini EfalseDifferent factors affecting human ANP amyloid aggregation and their implications in congestive heart failure.<h4>Aims</h4>Atrial Natriuretic Peptide (ANP)-containing amyloid is frequently found in the elderly heart. No data exist regarding ANP aggregation process and its link to pathologies. Our aims were: i) to experimentally prove the presumptive association of Congestive Heart Failure (CHF) and Isolated Atrial Amyloidosis (IAA); ii) to characterize ANP aggregation, thereby elucidating IAA implication in the CHF pathogenesis.<h4>Methods and results</h4>A significant prevalence (85%) of IAA was immunohistochemically proven ex vivo in biopsies from CHF patients. We investigated in vitro (using Congo Red, Thioflavin T, SDS-PAGE, transmission electron microscopy, infrared spectroscopy) ANP fibrillogenesis, starting from α-ANP as well as the ability of dimeric β-ANP to promote amyloid formation. Dif2011-01-01T00:00:00Z20112025-05-31T22:43:29.123Z2025-05-31T22:43:29.123ZS-EPMC31441992181455910.1371/journal.pone.0021870